Aurora Expands Leading Portfolio of High-Potency Medical Flower Products in Poland

Core Insights - Aurora Cannabis Inc. has launched a new proprietary cultivar named Black Jelly in Poland, enhancing its portfolio of high-potency medical cannabis products in a rapidly growing European market [1][2] - Black Jelly features a cannabinoid profile of THC 27% and CBD <1%, and is derived from a high-THC sativa strain [2] - The company emphasizes its advanced genetic breeding program and cultivation excellence as key factors in successfully introducing this product to the Polish market [2][3] Product Details - Black Jelly is characterized by dense, large flowers with green and orange hues, and a terpene profile that includes sweet black liquorice and fruity undertones [2] - The product is grown and manufactured in Aurora's Canadian facilities that are certified under GACP and EU-GMP standards [1][2] Market Position - Aurora Cannabis continues to strengthen its leadership in the international medical cannabis sector, leveraging scientific expertise and regulatory knowledge to support patient access and market growth across Europe [3] - The company has over a decade of experience in global medical markets, positioning itself as a trusted partner in advancing Poland's medical cannabis ecosystem [3] Company Overview - Aurora Cannabis operates in both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a diverse brand portfolio [4] - The company also holds a controlling interest in Bevo Farms Ltd., a leading supplier of propagated agricultural plants in North America [5]